Carmela Mendoza

Carmela Mendoza

Carmela Mendoza is a senior reporter for Private Equity International based in London. She first joined PEI in Hong Kong in 2015 and covered Asia. A graduate of Ateneo de Manila University, she previously worked for a digital agency in Singapore focused on government websites and publications covering business, trade and industry, transport, and social development.

SoftBank Vision Fund portfolio starts to take shape

The tech giant led investments of more than $300m in US-based indoor farming company Plenty and self-driving technology specialist Brain Corp.

2 min read · 20 July 2017

Updated: NPS CIO resigns

Myoun-Wook Kang, who joined the Korean pension fund in February 2016, is leaving the firm after a wave of key personnel departures early this year.

2 min read · 19 July 2017

CITIC Capital partners with 3i for cross-border push

The pair have teamed up for the first time, investing between them €227 million for Formel D, a global service provider to the automotive and component supply industry.

2 min read · 19 July 2017

Ex-Partners exec to lead Hamilton Lane’s Australia expansion

The $342bn asset manager has made its first Australia-focused hire as it looks to raise capital from the country, as well as gaining access to greater deal flow.

2 min read · 18 July 2017

Australia sees rise of spin-outs

The private equity industry Down Under is undergoing a generational shift, with a crop of new groups emerging from established players.

3 min read · 17 July 2017

APAC H1 fundraising rebounds

Fundraising in the region picked up in the first six months of 2017 compared to the same period a year ago, largely boosted by KKR’s $9.3bn pan-Asian fund.

2 min read · 17 July 2017

Quadria sets target of up to $450m for next fund

Singapore-based Quadria Capital, which recently struck two deals in Indonesia and Vietnam, looks set to launch its next healthcare fund in 2018, says founder Abrar Mir.

2 min read · 17 July 2017

Warburg Pincus improves liquidity in blood company

Over nearly seven years, Warburg more than doubled EBITDA at China Biologic Products and created a booming plasma-based drugs company.

4 min read · 14 July 2017

Korean institutional investors move towards alternatives

The low interest rate environment and a shrinking domestic market means Korean institutional investors have nowhere to go but alternatives.

5 min read · 14 July 2017

Navis favours side pocket for future funds – Exclusive

The pan-Asian manager is considering modifying its portfolio construction philosophy for future funds to include around 15 much smaller deals alongside its core $50m to $150m range.

3 min read · 13 July 2017

Showing 1,251 to 1,260 of 1,813 results
1…125127…182